{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:15:12Z","timestamp":1791544512049,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pharvaris Netherlands B.V."},{"name":"Adelphi Values"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09132-4","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:59:59Z","timestamp":1772445599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing Patient-Reported Outcomes in Acute Attacks of Hereditary Angioedema: Insights from a Mixed Methods Study of Participants Receiving Standard-of-Care Treatments in a Real-World Setting"],"prefix":"10.1007","volume":"69","author":[{"given":"Joan","family":"Mendivil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gargon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Helene","family":"Jouvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fairbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Middlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"1","key":"9132_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA et al (2021) US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract 9(1):132\u2013150e133. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"9132_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"PJ Busse","year":"2020","unstructured":"Busse PJ, Christiansen SC (2020) Hereditary angioedema. N Engl J Med 382(12):1136\u20131148. https:\/\/doi.org\/10.1056\/NEJMra1808012","journal-title":"N Engl J Med"},{"issue":"1","key":"9132_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M et al (2021) Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis 16(1):94. https:\/\/doi.org\/10.1186\/s13023-021-01717-4","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"9132_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM et al (2020) Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol 124(6):600\u2013607. https:\/\/doi.org\/10.1016\/j.anai.2020.02.018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"9132_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-021-00550-5","volume":"17","author":"J Anderson","year":"2021","unstructured":"Anderson J, Levy DS, Lumry W, Koochaki P, Lanar S, Henry Li H (2021) Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy. Allergy Asthma Clin Immunol 17(1):60. https:\/\/doi.org\/10.1186\/s13223-021-00550-5","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"9132_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-021-00563-0","volume":"17","author":"J Hews-Girard","year":"2021","unstructured":"Hews-Girard J, Goodyear MD (2021) Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study. Allergy Asthma Clin Immunol 17(1):61. https:\/\/doi.org\/10.1186\/s13223-021-00563-0","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"9132_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","volume":"35","author":"T Caballero","year":"2014","unstructured":"Caballero T, Aygoren-Pursun E, Bygum A et al (2014) The humanistic burden of hereditary angioedema: results from the burden of illness study in Europe. Allergy Asthma Proc 35(1):47\u201353. https:\/\/doi.org\/10.2500\/aap.2013.34.3685","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"9132_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT (2010) The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31(5):407\u2013414. https:\/\/doi.org\/10.2500\/aap.2010.31.3394","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"9132_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","volume":"154","author":"A Reshef","year":"2024","unstructured":"Reshef A, Buttgereit T, Betschel SD et al (2024) Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol 154(2):398\u2013411e391. https:\/\/doi.org\/10.1016\/j.jaci.2024.03.024","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"9132_CR10","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","volume":"41","author":"WR Lumry","year":"2020","unstructured":"Lumry WR, Settipane RA (2020) Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc 41(Suppl 1):S08\u2013S13. https:\/\/doi.org\/10.2500\/aap.2020.41.200050","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"9132_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/joim.12304","volume":"277","author":"M Mansi","year":"2015","unstructured":"Mansi M, Zanichelli A, Coerezza A et al (2015) Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med 277(5):585\u2013593. https:\/\/doi.org\/10.1111\/joim.12304","journal-title":"J Intern Med"},{"key":"9132_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108523","volume":"105","author":"A Lesage","year":"2022","unstructured":"Lesage A, Marceau F, Gibson C et al (2022) In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B(2) receptor antagonist in clinical development. Int Immunopharmacol 105:108523. https:\/\/doi.org\/10.1016\/j.intimp.2022.108523","journal-title":"Int Immunopharmacol"},{"issue":"suppl","key":"9132_CR13","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.anai.2022.08.596","volume":"129","author":"K Groen","year":"2022","unstructured":"Groen K, Crabb\u00e9 R, Knolle J, Gibson C, Lesage A, Lu P (2022) Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist. Ann Allergy Asthma Immunol 129(suppl):S32\u201333. https:\/\/doi.org\/10.1016\/j.anai.2022.08.596","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"9132_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.anai.2024.04.029","volume":"133","author":"TD Smith","year":"2024","unstructured":"Smith TD, Riedl MA (2024) The future of therapeutic options for hereditary angioedema. Ann Allergy Asthma Immunol 133(4):380\u2013390. https:\/\/doi.org\/10.1016\/j.anai.2024.04.029","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"9132_CR15","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jaip.2023.04.017","volume":"11","author":"SD Betschel","year":"2023","unstructured":"Betschel SD, Banerji A, Busse PJ, Cohn DM, Magerl M (2023) Hereditary angioedema: a review of the current and evolving treatment landscape. J Allergy Clin Immunol Pract 11(8):2315\u20132325. https:\/\/doi.org\/10.1016\/j.jaip.2023.04.017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9132_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00916","volume":"11","author":"A Lesage","year":"2020","unstructured":"Lesage A, Gibson C, Marceau F et al (2020) In vitro pharmacological profile of a new small molecule bradykinin B(2) receptor antagonist. Front Pharmacol 11:916. https:\/\/doi.org\/10.3389\/fphar.2020.00916","journal-title":"Front Pharmacol"},{"issue":"6","key":"9132_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jaip.2024.04.007","volume":"12","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Fijen LM, Apfelbacher C et al (2024) A core outcome set for efficacy of acute treatment of hereditary angioedema. J Allergy Clin Immunol Pract 12(6):1614\u20131621. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.007","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"9132_CR18","unstructured":"US Food and Drug Administration (2018) Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. https:\/\/www.fda.gov\/media\/116277\/download. Accessed December 12, 2025"},{"key":"9132_CR19","unstructured":"US Food and Drug Administration (2025) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments: guidance for industry, Food and Drug Administration staff, and other stakeholders. https:\/\/www.fda.gov\/media\/159500\/download. Accessed December 12, 2025"},{"issue":"9","key":"9132_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12288","volume":"13","author":"DM Cohn","year":"2023","unstructured":"Cohn DM, Aygoren-Pursun E, Bernstein JA et al (2023) Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. Clin Transl Allergy 13(9):e12288. https:\/\/doi.org\/10.1002\/clt2.12288","journal-title":"Clin Transl Allergy"},{"key":"9132_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CE.S24743","volume":"7","author":"B Floccard","year":"2012","unstructured":"Floccard B, Hautin E, Bouillet L, Coppere B, Allaouchiche B (2012) An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core Evid 7:105\u2013114. https:\/\/doi.org\/10.2147\/CE.S24743","journal-title":"Core Evid"},{"issue":"6","key":"9132_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","volume":"107","author":"WR Lumry","year":"2011","unstructured":"Lumry WR, Li HH, Levy RJ et al (2011) Randomized placebo-controlled trial of the Bradykinin B(2) receptor antagonist Icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107(6):529\u2013537. https:\/\/doi.org\/10.1016\/j.anai.2011.08.015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"9132_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532\u2013541. https:\/\/doi.org\/10.1056\/NEJMoa0906393","journal-title":"N Engl J Med"},{"issue":"9","key":"9132_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.amjmed.2011.12.016","volume":"125","author":"A Kusuma","year":"2012","unstructured":"Kusuma A, Relan A, Knulst AC et al (2012) Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 125(9):937.e917\u2013924. https:\/\/doi.org\/10.1016\/j.amjmed.2011.12.016","journal-title":"Am J Med"},{"issue":"2","key":"9132_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11597490-000000000-00000","volume":"5","author":"CV McMillan","year":"2012","unstructured":"McMillan CV, Speight J, Relan A, Bellizzi L, Haase G, Cicardi M (2012) Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study. Patient 5(2):113\u2013126. https:\/\/doi.org\/10.2165\/11597490-000000000-00000","journal-title":"Patient"},{"key":"9132_CR26","unstructured":"US Food and Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/media\/77832\/download. Accessed December 12, 2025"},{"key":"9132_CR27","unstructured":"National Organization for Rare Disorders (2021) Hereditary angioedema. https:\/\/rarediseases.org\/rare-diseases\/hereditary-angioedema. Accessed December 12, 2025"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09132-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:59:41Z","timestamp":1773302381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9132"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09132-4","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"was obtained from Western Copernicus Group Independent Review Board (IRB number: 20225798) prior to the conduct of any study activities. All participants provided written informed consent after being provided with full information about the study. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"JMe is an employee of Pharvaris GmbH. LZ, MC, and PL are employees of Pharvaris Inc. NB, EG, HF, JS, JMi, and PC are employees of Adelphi Values, which received funding for this study from Pharvaris Inc. M-HJ was an employee of Pharvaris Inc. at the time that the study was conducted. LA-W has received consultancy fees from Pharvaris and Takeda. DMC has received consultancy fees from Astria, BioCryst, CSL Behring, Ionis, Intellia, KalVista, Otsuka, Pharvaris, Takeda; speaking fees from CSL Behring, Ionis, Takeda. MAR has received research grant support, consultancy fees, speaker fees, and\/or clinical trial fees from Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14"}}